Home > Products > CD3 & VEGFR1 > Recombinant Anti-CD3 x Anti-VEGFR1 Bispecific Antibody (Tandem scFv)

Recombinant Anti-CD3 x Anti-VEGFR1 Bispecific Antibody (Tandem scFv)  (CAT#: BSFV-108)

Recombinant Anti-CD3 x Anti-VEGFR1 Bispecific Antibody (Tandem scFv) is designed to be expressed as a scFv from an anti-CD3 antibody variable domains fused with a scFv from an anti-VEGFR1 antibody variable domains. It contains a His-tag at the C/N terminus for affinity purification. The BsAb exits as monomer in reducing and non-reducing conditions. This BsAb can retarget T cells to tumor cells. It is designed for the research of Colon cancer; Rectal cancer therapy.
Datasheet INQUIRY

Specifications

Targets
CD3 & VEGFR1
Type
Tandem scFv
Species Reactivity
Human
Application
FuncS; Promising therapeutic agent
Related Disease
Colon cancer; Rectal cancer

Targets

Target 1
CD3
Gene ID
UniProt ID
Alternative Names
CD3; CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3
Target 2
VEGFR1
Gene ID
UniProt ID
Alternative Names
FLT1; fms-related tyrosine kinase 1; FLT; FLT-1; VEGFR1; VEGFR-1; vascular endothelial growth factor receptor 1; fms-like tyrosine kinase 1; tyrosine-protein kinase FRT; tyrosine-protein kinase receptor FLT; vascular permeability factor receptor; fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor)
Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.
Online Inquiry

Related products of "CD3 & VEGFR1"

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD3 x Anti-VEGFR1 Bispecific Antibody (Tandem scFv) (BSFV-108). Click the button below to contact us or submit your feedback about this product.